Navigation Links
Biomoda Hires Senior Scientist to Expand Research & Development Effort
Date:1/11/2008

ALBUQUERQUE, N.M., Jan. 11 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, announced today Dr. Stephen M. Gomez has joined Biomoda as a Senior Research Specialist focused on the company's efforts to commercialize its assay for the early detection of lung cancer.

Dr. Gomez most recently worked as an associate research scientist at Lovelace Respiratory Research Institute in Albuquerque. He was an instructor in genetics at the University of New Mexico and consultant to national laboratories and UCLA. He is the author of nearly a dozen publications on proteomics and photosystems including his dissertation at the University of California, Los Angeles, on pigment-binding proteins.

"Dr. Gomez's experience and expertise in molecular, cell and development biology is of particular importance and use at Biomoda where we have developed a mechanism that preferentially binds to cancer cells and glows red under a microscope for easy and accurate detection of the disease," explained John Cousins, President of Biomoda. "I am pleased to have him working side-by-side with our team of exceptional scientists in the development and application of our assay by the medical community."

Dr. Gomez was awarded a Masters of Biology by the University of California before going on the get his Ph.D. in Molecular, Cell and Development Biology from the same institution. He holds a bachelors degree in biology from the California Institute of Technology, Pasadena.

Biomoda's patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Contact: John Cousins

(505) 821-0875


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biomoda Announces Collaborative Agreement With New Mexico Tech
2. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
3. Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts
4. WallSt.net Announces Upcoming Interview With CEO of Biomoda
5. Ventria Expands Team and Hires Kansan as Director of Bioprocessing Operations
6. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
7. MedImmune Announces Seven Key Promotions and New Hires
8. Diplomat Specialty Pharmacy Hires Vice President of Managed Markets
9. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
10. Phlo Affiliate Hires Chief Marketing Officer With Extensive Global Experience
11. Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in ... 8:30aET on RFD-TV. , With global population estimates nearing ten billion people by ... feed a growing nation. At the same time, many of our valuable resources are ...
(Date:10/7/2017)... (PRWEB) , ... October 06, ... ... years’ experience providing advanced instruments and applications consulting for microscopy and surface ... expertise in application consulting, Nanoscience Analytical offers a broad range of contract ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October ... on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker ... is free and open to the public, but registration is required. , WHAT: ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):